Reviewed,
UniProtKB/Swiss-Prot O43707 (ACTN4_HUMAN)
Last modified
September 2, 2008.
Version 104.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Alpha-actinin-4 Alternative name(s): Non-muscle alpha-actinin 4 F-actin cross-linking protein | ||
| Gene names |
| ||
| Organism | Homo sapiens (Human) | ||
| Taxonomic identifier | 9606 [NCBI] | ||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 911 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | F-actin cross-linking protein which is thought to anchor actin to a variety of intracellular structures. This is a bundling protein. |
| Subunit structure | Homodimer; antiparallel By similarity. Binds TRIM3 at the N-terminus By similarity. Interacts with BAIAP1 and PDLIM2. |
| Subcellular location | Nucleus. Cytoplasm. Note= Colocalizes with actin stress fibers. Nuclear translocation can be induced by the PI3 kinase inhibitor wortmannin or by cytochalasin D. Exclusively localized in the nucleus in a limited number of cell lines (breast cancer cell line MCF7, oral floor cancer IMC2, and bladder cancer KU7). |
| Tissue specificity | Widely expressed. |
| Involvement in disease | Cytoplasmic localization of ACTN4 may be associated with cancer metastases due to enhanced cell motility. Defects in ACTN4 are the cause of focal segmental glomerulosclerosis 1 (FSGS1) [MIM:603278]. FSGS1 is a common renal lesion characterized by increased urinary protein excretion (proteinuria) and decreasing kidney function (nephrotic syndrome). Renal insufficiency often progresses to end-stage renal disease (ESRD) (also known as end-stage renal failure), a highly morbid state requiring either dialysis therapy or kidney transplantation. FSGS1 is defined by the presence of segmental sclerosis in glomeruli, and is seen in all ethnic groups, although it is particularly common in individuals of African descent. FSGS1 occurs as an isolated primary condition or secondary to disorders as HIV infection, obesity, hypertension and diabetes. FSGS1 may also be inherited as a Mendelian trait. |
| Sequence similarities | Belongs to the alpha-actinin family. Contains 1 actin-binding domain. Contains 2 CH (calponin-homology) domains. Contains 2 EF-hand domains. Contains 4 spectrin repeats. |
| Sequence caution | The sequence AAC17470.1 differs from that shown. Reason: Frameshift at several positions. The sequence AAC17470.1 differs from that shown. Reason: Miscellaneous discrepancy. Sequencing errors. Compared to other mammalian sequences. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| CTNNB1 | P35222 | 1 | EBI-351526,EBI-491549 | |
| TJP1 | Q07157 | 2 | EBI-351526,EBI-79553 |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | |||||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 911 | 911 | Alpha-actinin-4 | ||||||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||||
| Domain | 1 – 269 | 269 | Actin-binding | ||||||||||||||||||||||||||||||||||||||
| Domain | 50 – 154 | 105 | CH 1 | ||||||||||||||||||||||||||||||||||||||
| Domain | 163 – 269 | 107 | CH 2 | ||||||||||||||||||||||||||||||||||||||
| Repeat | 293 – 403 | 111 | Spectrin 1 | ||||||||||||||||||||||||||||||||||||||
| Repeat | 413 – 518 | 106 | Spectrin 2 | ||||||||||||||||||||||||||||||||||||||
| Repeat | 528 – 639 | 112 | Spectrin 3 | ||||||||||||||||||||||||||||||||||||||
| Repeat | 649 – 752 | 104 | Spectrin 4 | ||||||||||||||||||||||||||||||||||||||
| Domain | 765 – 800 | 36 | EF-hand 1 | ||||||||||||||||||||||||||||||||||||||
| Domain | 806 – 841 | 36 | EF-hand 2 | ||||||||||||||||||||||||||||||||||||||
| Calcium binding | 778 – 789 | 12 | 1 Potential | ||||||||||||||||||||||||||||||||||||||
| Calcium binding | 819 – 830 | 12 | 2 Potential | ||||||||||||||||||||||||||||||||||||||
| Region | 177 – 192 | 16 | Polyphosphoinositide (PIP2)-binding Potential | ||||||||||||||||||||||||||||||||||||||
| Compositional bias | 19 – 26 | 8 | Poly-Gly | ||||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||||
| Modified residue | 265 | 1 | Phosphotyrosine | ||||||||||||||||||||||||||||||||||||||
| Cross-link | 378 | Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) | |||||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||||
| Natural variant | 255 | 1 | K → E in FSGS1. | ||||||||||||||||||||||||||||||||||||||
| Natural variant | 259 | 1 | T → I in FSGS1. | ||||||||||||||||||||||||||||||||||||||
| Natural variant | 262 | 1 | S → P in FSGS1. | ||||||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 60 | 1 | C → S in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 124 | 1 | V → I Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 164 | 1 | S → L in AL047603 and AU118403. Ref.4 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 276 | 1 | T → TET Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 292 – 294 | 3 | EHL → CSTS in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 359 – 360 | 2 | TL → SV in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 476 | 1 | I → S in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 526 | 1 | I → II in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 536 | 1 | R → P in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 645 | 1 | Q → QQ in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 673 – 674 | 2 | GR → A in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 850 | 1 | A → T in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 859 | 1 | Missing Ref.3 | ||||||||||||||||||||||||||||||||||||||
| Sequence conflict | 891 – 893 | 3 | AVP → GVR in AAC17470. Ref.3 | ||||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||||
| Helix | 47 – 64 | 18 | |||||||||||||||||||||||||||||||||||||||
| Helix | 65 – 67 | 3 | |||||||||||||||||||||||||||||||||||||||
| Turn | 74 – 80 | 7 | |||||||||||||||||||||||||||||||||||||||
| Helix | 82 – 92 | 11 | |||||||||||||||||||||||||||||||||||||||
| Helix | 105 – 120 | 16 | |||||||||||||||||||||||||||||||||||||||
| Turn | 121 – 123 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 131 – 135 | 5 | |||||||||||||||||||||||||||||||||||||||
| Helix | 139 – 153 | 15 | |||||||||||||||||||||||||||||||||||||||
| Turn | 154 – 157 | 4 | |||||||||||||||||||||||||||||||||||||||
| Helix | 165 – 177 | 13 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 187 – 189 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 190 – 192 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 196 – 205 | 10 | |||||||||||||||||||||||||||||||||||||||
| Helix | 207 – 209 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 212 – 214 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 220 – 234 | 15 | |||||||||||||||||||||||||||||||||||||||
| Helix | 243 – 248 | 6 | |||||||||||||||||||||||||||||||||||||||
| Beta strand | 249 – 251 | 3 | |||||||||||||||||||||||||||||||||||||||
| Helix | 254 – 267 | 14 | |||||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||
References
| « Hide 'large scale' references | |
| [1] | "Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion." Honda K., Yamada T., Endo R., Ino Y., Gotoh M., Tsuda H., Yamada Y., Chiba H., Hirohashi S. J. Cell Biol. 140:1383-1393(1998) [PubMed: 9508771] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 4-911. |
| [2] | Erratum Honda K., Yamada T., Endo R., Ino Y., Gotoh M., Tsuda H., Yamada Y., Chiba H., Hirohashi S. J. Cell Biol. 143:276-276(1998) |
| [3] | "The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells." Nikolopoulos S.N., Spengler B.A., Kisselbach K., Evans A.E., Biedler J.L., Ross R.A. Oncogene 19:380-386(2000) [PubMed: 10656685] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA]. Tissue: Neuroblastoma. |
| [4] | "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)." The MGC Project Team Genome Res. 14:2121-2127(2004) [PubMed: 15489334] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. Tissue: Placenta. |
| [5] | The German cDNA consortium Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-170. Tissue: Uterus. |
| [6] | Isogai T., Otsuki T., Sugiyama T. Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 1-218. |
| [7] | "Interaction of two actin-binding proteins, synaptopodin and alpha-actinin-4, with the tight junction protein MAGI-1." Patrie K.M., Drescher A.J., Welihinda A., Mundel P., Margolis B. J. Biol. Chem. 277:30183-30190(2002) [PubMed: 12042308] [Abstract] Cited for: INTERACTION WITH BAIAP1. |
| [8] | "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells." Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H., Zha X.-M., Polakiewicz R.D., Comb M.J. Nat. Biotechnol. 23:94-101(2005) [PubMed: 15592455] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-265, MASS SPECTROMETRY. |
| [9] | "Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer." Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M. Comb M.J.Cell 131:1190-1203(2007) [PubMed: 18083107] [Abstract] Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-265, MASS SPECTROMETRY. |
| [10] | "Tryptic digestion of ubiquitin standards reveals an improved strategy for identifying ubiquitinated proteins by mass spectrometry." Denis N.J., Vasilescu J., Lambert J.-P., Smith J.C., Figeys D. Proteomics 7:868-874(2007) [PubMed: 17370265] [Abstract] Cited for: UBIQUITINATION [LARGE SCALE ANALYSIS] AT LYS-378, MASS SPECTROMETRY. |
| [11] | "Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis." Kaplan J.M., Kim S.H., North K.N., Rennke H., Correia L.A., Tong H.-Q., Mathis B.J., Rodriguez-Perez J.-C., Allen P.G., Beggs A.H., Pollak M.R. Nat. Genet. 24:251-256(2000) [PubMed: 10700177] [Abstract] Cited for: VARIANTS FSGS1 GLU-255; ILE-259 AND PRO-262. Tissue: Lymphocyte. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D89980 mRNA. Translation: BAA24447.1. Different initiation. U48734 mRNA. Translation: AAC17470.1. Sequence problems. BC005033 mRNA. Translation: AAH05033.1. AL047603 mRNA. No translation available. AU118403 mRNA. No translation available. | |||||||||||||||||||||||||
| RefSeq | NP_004915.2. | ||||||||||||||||||||||||
| UniGene | Hs.270291 | ||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| SMR | O43707. Positions 44-911. | ||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||
| IntAct | O43707. | ||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||
| PhosphoSite | O43707. | ||||||||||||||||||||||||
2-D gel databases | |||||||||||||||||||||||||
| REPRODUCTION-2DPAGE | O43707. | ||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||
| PeptideAtlas | O43707. | ||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||
| Ensembl | ENSG00000130402. Homo sapiens. [Contig view] | ||||||||||||||||||||||||
| GeneID | 81. | ||||||||||||||||||||||||
| KEGG | hsa:81. | ||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||
| H-InvDB | HIX0015097. | ||||||||||||||||||||||||
| HGNC | HGNC:166. ACTN4. | ||||||||||||||||||||||||

Clusters with